BiotechTube

Daptomycin + Daptomycin

Phase 3Terminated
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Febrile Neutropenia

Conditions

Febrile Neutropenia

Trial Timeline

Apr 1, 2011 → Apr 1, 2013

NCT ID
NCT01216241

About Daptomycin + Daptomycin

Daptomycin + Daptomycin is a phase 3 stage product being developed by Merck for Febrile Neutropenia. The current trial status is terminated. This product is registered under clinical trial identifier NCT01216241. Target conditions include Febrile Neutropenia.

What happened to similar drugs?

4 of 7 similar drugs in Febrile Neutropenia were approved

Approved (4) Terminated (3) Active (2)
✅Imipenem + ImipenemMerckApproved
✅Ceftolozane-Tazobactam + MeropenemMerckApproved
✅Ceftolozane-tazobactam IVMerckApproved
✅Liposomal amphotericin B (AmBisome®) + Liposomal amphotericin B (AmBisome®)Gilead SciencesApproved
❌HHPG-19K InjectionJiangsu Hengrui MedicinePhase 3
🔄linezolid + vancomycinPfizerPhase 3
🔄ciprofloxacin + cefepimeBayerPhase 3

Hype Score Breakdown

Clinical
17
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT01216241Phase 3Terminated
NCT00882557Phase 1Completed

Competing Products

8 competing products in Febrile Neutropenia

See all competitors
ProductCompanyStageHype Score
HHPG-19K InjectionJiangsu Hengrui MedicinePhase 3
32
Imipenem + ImipenemMerckApproved
43
Ceftolozane-Tazobactam + MeropenemMerckApproved
50
Ceftolozane-tazobactam IVMerckApproved
35
Liposomal amphotericin B (AmBisome®) + Liposomal amphotericin B (AmBisome®)Gilead SciencesApproved
35
linezolid + vancomycinPfizerPhase 3
40
Antibacterial agent for the treatment of febrile neutropeniaPfizerPre-clinical
26
ciprofloxacin + cefepimeBayerPhase 3
37